In metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first-line treatment. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.